2016
Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma.
Abu-Khalaf MM, Raza MA, Hatzis C, Wang H, Lin K, Higgins S, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Santin AD, Schwartz PE. Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. European Journal Of Gynaecological Oncology 2016, 37: 199-203. PMID: 27172745.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnemiaAntineoplastic Combined Chemotherapy ProtocolsBrachytherapyCarcinosarcomaChemoradiotherapyCisplatinDisease-Free SurvivalFemaleHumansIfosfamideMesnaMiddle AgedNeoplasm StagingNeutropeniaProtective AgentsRetrospective StudiesTreatment OutcomeUterine NeoplasmsConceptsVaginal cuff brachytherapyProgression-free survivalFirst-line treatmentOverall survivalUterine carcinosarcomaStage ILine treatmentStage IIIDay 1Anemia grade 1Most common toxicitiesNeutropenia grade 3Cycles of cisplatinMedian overall survivalStage IV diseaseCommon toxicitiesMedian followTreatment discontinuationFree survivalPatient withdrawalCombination cisplatinDose modificationMedian ageRetrospective studyGrade 3
2010
Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro
Cross SN, Cocco E, Bellone S, Anagnostou VK, Brower SL, Richter CE, Siegel ER, Schwartz PE, Rutherford TJ, Santin AD. Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro. American Journal Of Obstetrics And Gynecology 2010, 203: 162.e1-162.e8. PMID: 20417484, PMCID: PMC2918912, DOI: 10.1016/j.ajog.2010.02.056.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsApoptosisCarboplatinCell Line, TumorCell ProliferationCisplatinCystadenocarcinoma, PapillaryCystadenocarcinoma, SerousDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedProbabilityReceptor, ErbB-2Sensitivity and SpecificityUterine NeoplasmsConceptsSingle-agent chemotherapyLow HER-2/neu expressionCell linesHER-2/neu expressionEffective chemotherapy regimensPlatinum-based chemotherapySerous papillary adenocarcinomaHalf-maximum inhibitory concentrationPlatinum compoundsLow half-maximum inhibitory concentrationChemotherapy regimensAdverse prognosisPapillary adenocarcinomaCarcinoma cell linesNeu expressionNeu overexpressionChemotherapy agentsPapillary carcinoma cell line
2004
Current treatment options for endometrial cancer
Santin AD, Bellone S, O’Brien T, Pecorelli S, Cannon MJ, Roman JJ. Current treatment options for endometrial cancer. Expert Review Of Anticancer Therapy 2004, 4: 679-689. PMID: 15270671, DOI: 10.1586/14737140.4.4.679.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCell DifferentiationCisplatinDoxorubicinEndometrial NeoplasmsFemaleHumansHysterectomyNeoplasm InvasivenessNeoplasm Recurrence, LocalOvariectomyPaclitaxelPrognosisRadiotherapy, AdjuvantReceptor, ErbB-2Risk FactorsSurvival AnalysisTrastuzumabConceptsEndometrial cancerMyometrial invasionStage I endometrial cancer patientsLow-toxicity regimenEndometrial cancer patientsLymph node dissectionRecurrent endometrial cancerTotal abdominal hysterectomyClear cell histologyCornerstone of treatmentPostoperative radiation therapyImportant prognostic factorCurrent treatment optionsCombination of cisplatinFemale genital tractAttractive therapeutic strategyMajority of casesType II receptorExtrapelvic recurrenceAbdominal hysterectomyNode dissectionPelvic radiotherapyPelvic recurrenceSystemic chemotherapyVaginal bleeding
2000
Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix
Santin A, Hermonat P, Ravaggi A, Bellone S, Roman J, Pecorelli S, Cannon M, Parham G. Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. International Journal Of Radiation Oncology • Biology • Physics 2000, 48: 997-1006. PMID: 11072156, DOI: 10.1016/s0360-3016(00)00769-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsCisplatinCombined Modality TherapyFemaleHumansImmunity, CellularInterferon-gammaInterleukin-2Killer Cells, NaturalLymphocyte ActivationLymphocyte SubsetsMembrane GlycoproteinsMiddle AgedPerforinPore Forming Cytotoxic ProteinsProspective StudiesReceptors, Interleukin-2Uterine Cervical NeoplasmsConceptsT cellsIL-2Lymphoblast transformationRadiation therapyImmune functionNatural killer cytotoxic activityCD25-positive lymphocytesRadiation-induced immunosuppressionPercentage of CD8Advanced cervical cancerT cell numbersNatural killer cellsT cell subsetsActivation markers CD25C-RTMean absolute numberB cell numbersK562 cellsCisplatinum administrationConcurrent cisplatinumLymphocyte subsetsNK cellsConcurrent administrationKiller cellsUterine cervix
1994
Follow-up after Primary Therapy: Management of the Symptomatic Patient—Surgery
Pecorelli S, Sartori E, Santin A. Follow-up after Primary Therapy: Management of the Symptomatic Patient—Surgery. Gynecologic Oncology 1994, 55: s138-s142. PMID: 7835798, DOI: 10.1006/gyno.1994.1353.Peer-Reviewed Original ResearchConceptsSecondary surgeryStage IIICCisplatin chemotherapyStage INegative second-look surgeryMacroscopic residual tumorNegative second lookSecond-line chemotherapyEvidence of diseaseResidual tumor volumeSecond-look surgeryImportant prognostic parameterBowel obstructionPelvic recurrencePrimary surgeryPrimary therapyMost patientsPalliative roleResidual tumorPatients surgeryPrognostic parametersDefinitive procedureDegree of differentiationVisible tumorTumor volume